Nature Biotechnology - Issue - nature.com science feeds Nature Biotechnology journal featuring biotechnology articles and science research papers of commercial interest in pharmaceutical, medical, and environmental sciences. http://www.nature.com/nbt/current_issue/ Nature Publishing Group en © 2012 Nature Publishing Group Nature Biotechnology 1087-0156 1546-1696 © 2012 Nature Publishing Group permissions@nature.com Nature Biotechnology http://www.nature.com/includes/rj_globnavimages/nbt_logo.gif http://www.nature.com/nbt/ In this issue http://feeds.nature.com/~r/nbt/rss/current/~3/Ocg1IoMuYCE/nbt.2233 Advertisment

In this issue

Nature Biotechnology 30, vii (2012). doi:10.1038/nbt.2233

]]> In this issue doi:10.1038/nbt.2233 Nature Biotechnology 30, vii (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2233 http://dx.doi.org/10.1038/nbt.2233 30 5 In This Issue vii viii http://dx.doi.org/10.1038/nbt.2233 Shining a light on trial data http://feeds.nature.com/~r/nbt/rss/current/~3/a1wtZnYU91M/nbt.2237 The European Medicines Agency's request to make all clinical trial data available is key to countering bias in publication, drug prescription practice and health policy. Shining a light on trial data

Nature Biotechnology 30, 371 (2012). doi:10.1038/nbt.2237

The European Medicines Agency's request to make all clinical trial data available is key to countering bias in publication, drug prescription practice and health policy.

]]> Shining a light on trial data doi:10.1038/nbt.2237 Nature Biotechnology 30, 371 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2237 http://dx.doi.org/10.1038/nbt.2237 30 5 Editorial 371 371 http://dx.doi.org/10.1038/nbt.2237 Biomarkers unbound http://feeds.nature.com/~r/nbt/rss/current/~3/s24eGbK6dWU/nbt.2221 Controversies surrounding government walk-in rights or patent eligibility that grabbed headlines in recent weeks presage broader changes in biomarker patenting. Biomarkers unbound

Nature Biotechnology 30, 372 (2012). doi:10.1038/nbt.2221

Controversies surrounding government walk-in rights or patent eligibility that grabbed headlines in recent weeks presage broader changes in biomarker patenting.

]]> Biomarkers unbound doi:10.1038/nbt.2221 Nature Biotechnology 30, 372 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2221 http://dx.doi.org/10.1038/nbt.2221 30 5 Editorial 372 372 http://dx.doi.org/10.1038/nbt.2221 Industry reels as Prometheus falls and Myriad faces further reviews http://feeds.nature.com/~r/nbt/rss/current/~3/OB6xXKsv04I/nbt0512-373 Industry reels as Prometheus falls and Myriad faces further reviews

Nature Biotechnology 30, 373 (2012). doi:10.1038/nbt0512-373

Author: Jeffrey L. Fox

]]> Industry reels as Prometheus falls and Myriad faces further reviews Jeffrey L. Fox doi:10.1038/nbt0512-373 Nature Biotechnology 30, 373 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-373 http://dx.doi.org/10.1038/nbt0512-373 30 5 News 373 374 http://dx.doi.org/10.1038/nbt0512-373 JAK pot for Galapagos http://feeds.nature.com/~r/nbt/rss/current/~3/gXhM-VONunM/nbt0512-374 JAK pot for Galapagos

Nature Biotechnology 30, 374 (2012). doi:10.1038/nbt0512-374

Author: Gunjan Sinha

]]> JAK pot for Galapagos Gunjan Sinha doi:10.1038/nbt0512-374 Nature Biotechnology 30, 374 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-374 http://dx.doi.org/10.1038/nbt0512-374 30 5 News 374 374 http://dx.doi.org/10.1038/nbt0512-374 Stromedix acquisition signals growing interest in fibrosis http://feeds.nature.com/~r/nbt/rss/current/~3/d9Lbmb0kbvI/nbt0512-375 Stromedix acquisition signals growing interest in fibrosis

Nature Biotechnology 30, 375 (2012). doi:10.1038/nbt0512-375

Author: Malorye Allison

]]> Stromedix acquisition signals growing interest in fibrosis Malorye Allison doi:10.1038/nbt0512-375 Nature Biotechnology 30, 375 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-375 http://dx.doi.org/10.1038/nbt0512-375 30 5 News 375 376 http://dx.doi.org/10.1038/nbt0512-375 1000 genomes on Amazon's cloud http://feeds.nature.com/~r/nbt/rss/current/~3/mhD3xcqRfDE/nbt0512-376 1000 genomes on Amazon's cloud

Nature Biotechnology 30, 376 (2012). doi:10.1038/nbt0512-376

Author: Emily Waltz

]]> 1000 genomes on Amazon's cloud Emily Waltz doi:10.1038/nbt0512-376 Nature Biotechnology 30, 376 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-376 http://dx.doi.org/10.1038/nbt0512-376 30 5 News 376 376 http://dx.doi.org/10.1038/nbt0512-376 Affymax poised to challenge Amgen http://feeds.nature.com/~r/nbt/rss/current/~3/MjuAm1vN8CE/nbt0512-377 Affymax poised to challenge Amgen

Nature Biotechnology 30, 377 (2012). doi:10.1038/nbt0512-377

Author: Nuala Moran

]]> Affymax poised to challenge Amgen Nuala Moran doi:10.1038/nbt0512-377 Nature Biotechnology 30, 377 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-377 http://dx.doi.org/10.1038/nbt0512-377 30 5 News 377 379 http://dx.doi.org/10.1038/nbt0512-377 UK biotech's shot in the arm http://feeds.nature.com/~r/nbt/rss/current/~3/EgSMoNQiRQo/nbt0512-378 UK biotech's shot in the arm

Nature Biotechnology 30, 378 (2012). doi:10.1038/nbt0512-378

Author: Susan Aldridge

]]> UK biotech's shot in the arm Susan Aldridge doi:10.1038/nbt0512-378 Nature Biotechnology 30, 378 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-378 http://dx.doi.org/10.1038/nbt0512-378 30 5 News 378 378 http://dx.doi.org/10.1038/nbt0512-378 Texas legitimizes path around FDA oversight http://feeds.nature.com/~r/nbt/rss/current/~3/3RbZ5D3yWIU/nbt0512-379 Texas legitimizes path around FDA oversight

Nature Biotechnology 30, 379 (2012). doi:10.1038/nbt0512-379

Author: Laura DeFrancesco

]]> Texas legitimizes path around FDA oversight Laura DeFrancesco doi:10.1038/nbt0512-379 Nature Biotechnology 30, 379 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-379 http://dx.doi.org/10.1038/nbt0512-379 30 5 News 379 379 http://dx.doi.org/10.1038/nbt0512-379 Blood test for Down syndrome http://feeds.nature.com/~r/nbt/rss/current/~3/7eTTN8GKsa0/nbt0512-380a Blood test for Down syndrome

Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380a

Author: Jennifer Rohn

]]> Blood test for Down syndrome Jennifer Rohn doi:10.1038/nbt0512-380a Nature Biotechnology 30, 380 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-380a http://dx.doi.org/10.1038/nbt0512-380a 30 5 News 380 380 http://dx.doi.org/10.1038/nbt0512-380a Industry trial bias refuted http://feeds.nature.com/~r/nbt/rss/current/~3/jeDwe_bV7kU/nbt0512-380b Industry trial bias refuted

Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380b

Author: Josh P Roberts

]]> Industry trial bias refuted Josh P Roberts doi:10.1038/nbt0512-380b Nature Biotechnology 30, 380 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-380b http://dx.doi.org/10.1038/nbt0512-380b 30 5 News 380 380 http://dx.doi.org/10.1038/nbt0512-380b Fifth time's the charm for infant respiratory distress drug http://feeds.nature.com/~r/nbt/rss/current/~3/Iuxc0G5omjI/nbt0512-380c Fifth time's the charm for infant respiratory distress drug

Nature Biotechnology 30, 380 (2012). doi:10.1038/nbt0512-380c

Author: Alla Katsnelson

]]> Fifth time's the charm for infant respiratory distress drug Alla Katsnelson doi:10.1038/nbt0512-380c Nature Biotechnology 30, 380 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-380c http://dx.doi.org/10.1038/nbt0512-380c 30 5 News 380 380 http://dx.doi.org/10.1038/nbt0512-380c Hypoxia-activated prodrugs forge ahead in cancer http://feeds.nature.com/~r/nbt/rss/current/~3/apK5inqhMXQ/nbt0512-381 Hypoxia-activated prodrugs forge ahead in cancer

Nature Biotechnology 30, 381 (2012). doi:10.1038/nbt0512-381

Author: Jim Kling

]]> Hypoxia-activated prodrugs forge ahead in cancer Jim Kling doi:10.1038/nbt0512-381 Nature Biotechnology 30, 381 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-381 http://dx.doi.org/10.1038/nbt0512-381 30 5 News 381 381 http://dx.doi.org/10.1038/nbt0512-381 Around the world in a month http://feeds.nature.com/~r/nbt/rss/current/~3/Xt7f58qGohU/nbt0512-382 Around the world in a month

Nature Biotechnology 30, 382 (2012). doi:10.1038/nbt0512-382

]]> Around the world in a month doi:10.1038/nbt0512-382 Nature Biotechnology 30, 382 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-382 http://dx.doi.org/10.1038/nbt0512-382 30 5 News 382 382 http://dx.doi.org/10.1038/nbt0512-382 Drug pipeline: 1Q12 http://feeds.nature.com/~r/nbt/rss/current/~3/CKB3fzRUVXQ/nbt.2210 Drug pipeline: 1Q12

Nature Biotechnology 30, 383 (2012). doi:10.1038/nbt.2210

Author: Craig Mak

]]> Drug pipeline: 1Q12 Craig Mak doi:10.1038/nbt.2210 Nature Biotechnology 30, 383 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2210 http://dx.doi.org/10.1038/nbt.2210 30 5 News 383 383 http://dx.doi.org/10.1038/nbt.2210 Biotech equities heat up in 1Q12 http://feeds.nature.com/~r/nbt/rss/current/~3/kUW54c1m68M/nbt.2211 Biotech equities heat up in 1Q12

Nature Biotechnology 30, 384 (2012). doi:10.1038/nbt.2211

Author: Walter Yang

]]> Biotech equities heat up in 1Q12 Walter Yang doi:10.1038/nbt.2211 Nature Biotechnology 30, 384 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2211 http://dx.doi.org/10.1038/nbt.2211 30 5 News 384 384 http://dx.doi.org/10.1038/nbt.2211 Recasting natural product research http://feeds.nature.com/~r/nbt/rss/current/~3/kUg8TnujMMA/nbt.2208 Can the commercial sector capitalize on the merger of high-throughput technology and natural products? Cormac Sheridan investigates. Recasting natural product research

Nature Biotechnology 30, 385 (2012). doi:10.1038/nbt.2208

Author: Cormac Sheridan

Can the commercial sector capitalize on the merger of high-throughput technology and natural products? Cormac Sheridan investigates.

]]> Recasting natural product research Cormac Sheridan doi:10.1038/nbt.2208 Nature Biotechnology 30, 385 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2208 http://dx.doi.org/10.1038/nbt.2208 30 5 News 385 387 http://dx.doi.org/10.1038/nbt.2208 A work in progress http://feeds.nature.com/~r/nbt/rss/current/~3/NxqMR1eZfyg/nbt.2178 In life sciences, a successful company very often looks markedly different from what was envisioned at founding. A work in progress

Nature Biotechnology 30, 388 (2012). doi:10.1038/nbt.2178

Author: Bill Polvino

In life sciences, a successful company very often looks markedly different from what was envisioned at founding.

]]> A work in progress Bill Polvino doi:10.1038/nbt.2178 Nature Biotechnology 30, 388 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2178 http://dx.doi.org/10.1038/nbt.2178 30 5 Bioentrepreneur 388 389 http://dx.doi.org/10.1038/nbt.2178 High-efficiency TALEN-based gene editing produces disease-resistant rice http://feeds.nature.com/~r/nbt/rss/current/~3/6pDgFMfgyvg/nbt.2199 High-efficiency TALEN-based gene editing produces disease-resistant rice

Nature Biotechnology 30, 390 (2012). doi:10.1038/nbt.2199

Authors: Ting Li, Bo Liu, Martin H Spalding, Donald P Weeks & Bing Yang

]]> High-efficiency TALEN-based gene editing produces disease-resistant rice Ting Li Bo Liu Martin H Spalding Donald P Weeks Bing Yang doi:10.1038/nbt.2199 Nature Biotechnology 30, 390 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2199 http://dx.doi.org/10.1038/nbt.2199 30 5 Correspondence 390 392 http://dx.doi.org/10.1038/nbt.2199 How Europe's ethical divide looms over biotech law and patents http://feeds.nature.com/~r/nbt/rss/current/~3/fKcu1kmnCkI/nbt.2201 How Europe's ethical divide looms over biotech law and patents

Nature Biotechnology 30, 392 (2012). doi:10.1038/nbt.2201

Authors: George Gaskell, Sally Stares & Alain Pottage

]]> How Europe's ethical divide looms over biotech law and patents George Gaskell Sally Stares Alain Pottage doi:10.1038/nbt.2201 Nature Biotechnology 30, 392 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2201 http://dx.doi.org/10.1038/nbt.2201 30 5 Correspondence 392 394 http://dx.doi.org/10.1038/nbt.2201 The many faces of Bruton's tyrosine kinase http://feeds.nature.com/~r/nbt/rss/current/~3/FXpkFoPlpGs/nbt.2200 The many faces of Bruton's tyrosine kinase

Nature Biotechnology 30, 394 (2012). doi:10.1038/nbt.2200

Author: C Patrick McAtee

]]> The many faces of Bruton's tyrosine kinase C Patrick McAtee doi:10.1038/nbt.2200 Nature Biotechnology 30, 394 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2200 http://dx.doi.org/10.1038/nbt.2200 30 5 Correspondence 394 394 http://dx.doi.org/10.1038/nbt.2200 Biotech's wellspring: a survey of the health of the private sector http://feeds.nature.com/~r/nbt/rss/current/~3/89MM0GK6AkY/nbt.2209 An examination of the private biotech industry reveals shrinking financial resources and higher hurdles to obtain funding, but new models are evolving to meet the challenge. Biotech's wellspring: a survey of the health of the private sector

Nature Biotechnology 30, 395 (2012). doi:10.1038/nbt.2209

Author: Brady Huggett

An examination of the private biotech industry reveals shrinking financial resources and higher hurdles to obtain funding, but new models are evolving to meet the challenge.

]]> Biotech's wellspring: a survey of the health of the private sector Brady Huggett doi:10.1038/nbt.2209 Nature Biotechnology 30, 395 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2209 http://dx.doi.org/10.1038/nbt.2209 30 5 Feature 395 400 http://dx.doi.org/10.1038/nbt.2209 Biotech innovation in a first-to-file world http://feeds.nature.com/~r/nbt/rss/current/~3/PV2UaZkoPZc/nbt.2204 You may win the race, but can you take home the prize? Biotech innovation in a first-to-file world

Nature Biotechnology 30, 401 (2012). doi:10.1038/nbt.2204

Author: Jennifer A Camacho

You may win the race, but can you take home the prize?

]]> Biotech innovation in a first-to-file world Jennifer A Camacho doi:10.1038/nbt.2204 Nature Biotechnology 30, 401 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2204 http://dx.doi.org/10.1038/nbt.2204 30 5 Feature 401 403 http://dx.doi.org/10.1038/nbt.2204 Recent patent applications in genomic mapping http://feeds.nature.com/~r/nbt/rss/current/~3/jReO2x4tDbY/nbt.2217 Recent patent applications in genomic mapping

Nature Biotechnology 30, 404 (2012). doi:10.1038/nbt.2217

]]> Recent patent applications in genomic mapping doi:10.1038/nbt.2217 Nature Biotechnology 30, 404 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2217 http://dx.doi.org/10.1038/nbt.2217 30 5 Feature 404 404 http://dx.doi.org/10.1038/nbt.2217 Direct cloning of large genomic sequences http://feeds.nature.com/~r/nbt/rss/current/~3/LxYety7q13U/nbt.2207 The discovery of an efficient mechanism of homologous recombination between two linear DNA substrates provides a new method for direct cloning. Direct cloning of large genomic sequences

Nature Biotechnology 30, 405 (2012). doi:10.1038/nbt.2207

Authors: Ryan E Cobb & Huimin Zhao

The discovery of an efficient mechanism of homologous recombination between two linear DNA substrates provides a new method for direct cloning.

]]> Direct cloning of large genomic sequences Ryan E Cobb Huimin Zhao doi:10.1038/nbt.2207 Nature Biotechnology 30, 405 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2207 http://dx.doi.org/10.1038/nbt.2207 30 5 News and Views 405 406 http://dx.doi.org/10.1038/nbt.2207 Controlled drug release by a nanorobot http://feeds.nature.com/~r/nbt/rss/current/~3/_SLuiJl6ixk/nbt.2206 A tiny, locked box made of DNA opens up to release drug molecules in the presence of target cells. Controlled drug release by a nanorobot

Nature Biotechnology 30, 407 (2012). doi:10.1038/nbt.2206

Authors: Jinglin Fu & Hao Yan

A tiny, locked box made of DNA opens up to release drug molecules in the presence of target cells.

]]> Controlled drug release by a nanorobot Jinglin Fu Hao Yan doi:10.1038/nbt.2206 Nature Biotechnology 30, 407 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2206 http://dx.doi.org/10.1038/nbt.2206 30 5 News and Views 407 408 http://dx.doi.org/10.1038/nbt.2206 Cancer sequencing unravels clonal evolution http://feeds.nature.com/~r/nbt/rss/current/~3/0EGui4aeDbk/nbt.2213 Characterization of tumor heterogeneity at the sequence level presents new challenges and opportunities for targeted therapies. Cancer sequencing unravels clonal evolution

Nature Biotechnology 30, 408 (2012). doi:10.1038/nbt.2213

Author: Carlos Caldas

Characterization of tumor heterogeneity at the sequence level presents new challenges and opportunities for targeted therapies.

]]> Cancer sequencing unravels clonal evolution Carlos Caldas doi:10.1038/nbt.2213 Nature Biotechnology 30, 408 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2213 http://dx.doi.org/10.1038/nbt.2213 30 5 News and Views 408 410 http://dx.doi.org/10.1038/nbt.2213 Docetaxel-loaded nanoparticles shrink human tumors http://feeds.nature.com/~r/nbt/rss/current/~3/idxlmLXKv08/nbt.2223 Docetaxel-loaded nanoparticles shrink human tumors

Nature Biotechnology 30, 411 (2012). doi:10.1038/nbt.2223

Author: Susan Jones

]]> Docetaxel-loaded nanoparticles shrink human tumors Susan Jones doi:10.1038/nbt.2223 Nature Biotechnology 30, 411 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2223 http://dx.doi.org/10.1038/nbt.2223 30 5 Research Highlights 411 411 http://dx.doi.org/10.1038/nbt.2223 Engineering a thymus http://feeds.nature.com/~r/nbt/rss/current/~3/D_iJoV_8Q2Q/nbt.2225 Engineering a thymus

Nature Biotechnology 30, 411 (2012). doi:10.1038/nbt.2225

Author: Laura DeFrancesco

]]> Engineering a thymus Laura DeFrancesco doi:10.1038/nbt.2225 Nature Biotechnology 30, 411 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2225 http://dx.doi.org/10.1038/nbt.2225 30 5 Research Highlights 411 411 http://dx.doi.org/10.1038/nbt.2225 Zinc-finger nucleases hone tumor cell therapy http://feeds.nature.com/~r/nbt/rss/current/~3/71sqvkoKjCE/nbt.2227 Zinc-finger nucleases hone tumor cell therapy

Nature Biotechnology 30, 411 (2012). doi:10.1038/nbt.2227

Author: Jason Kreisberg

]]> Zinc-finger nucleases hone tumor cell therapy Jason Kreisberg doi:10.1038/nbt.2227 Nature Biotechnology 30, 411 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2227 http://dx.doi.org/10.1038/nbt.2227 30 5 Research Highlights 411 411 http://dx.doi.org/10.1038/nbt.2227 Drug lead for osteoarthritis http://feeds.nature.com/~r/nbt/rss/current/~3/GAEYPmN-Les/nbt.2229 Drug lead for osteoarthritis

Nature Biotechnology 30, 411 (2012). doi:10.1038/nbt.2229

Author: Craig Mak

]]> Drug lead for osteoarthritis Craig Mak doi:10.1038/nbt.2229 Nature Biotechnology 30, 411 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2229 http://dx.doi.org/10.1038/nbt.2229 30 5 Research Highlights 411 411 http://dx.doi.org/10.1038/nbt.2229 Pharmacogenomic profiling of cancer drugs http://feeds.nature.com/~r/nbt/rss/current/~3/t2RC8zFg8xM/nbt.2231 Pharmacogenomic profiling of cancer drugs

Nature Biotechnology 30, 411 (2012). doi:10.1038/nbt.2231

Author: Kathy Aschheim

]]> Pharmacogenomic profiling of cancer drugs Kathy Aschheim doi:10.1038/nbt.2231 Nature Biotechnology 30, 411 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2231 http://dx.doi.org/10.1038/nbt.2231 30 5 Research Highlights 411 411 http://dx.doi.org/10.1038/nbt.2231 Absolute quantification of somatic DNA alterations in human cancer http://feeds.nature.com/~r/nbt/rss/current/~3/a6xmElWu518/nbt.2203 Tumors vary in their ratio of normal to cancerous cells and in their genomic copy number. Carter et al. describe an analytic method for inferring the purity and ploidy of a tumor sample, enabling longitudinal studies of subclonal mutations and tumor evolution. Absolute quantification of somatic DNA alterations in human cancer

Nature Biotechnology 30, 413 (2012). doi:10.1038/nbt.2203

Authors: Scott L Carter, Kristian Cibulskis, Elena Helman, Aaron McKenna, Hui Shen, Travis Zack, Peter W Laird, Robert C Onofrio, Wendy Winckler, Barbara A Weir, Rameen Beroukhim, David Pellman, Douglas A Levine, Eric S Lander, Matthew Meyerson & Gad Getz

]]> Absolute quantification of somatic DNA alterations in human cancer Scott L Carter Kristian Cibulskis Elena Helman Aaron McKenna Hui Shen Travis Zack Peter W Laird Robert C Onofrio Wendy Winckler Barbara A Weir Rameen Beroukhim David Pellman Douglas A Levine Eric S Lander Matthew Meyerson Gad Getz doi:10.1038/nbt.2203 Nature Biotechnology 30, 413 (2012) 2012-04-29 Nature Biotechnology 2012-04-29 10.1038/nbt.2203 http://dx.doi.org/10.1038/nbt.2203 30 5 Computational Biology 413 421 http://dx.doi.org/10.1038/nbt.2203 B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study http://feeds.nature.com/~r/nbt/rss/current/~3/ypwrk1NX64o/nbt.2197 B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

Nature Biotechnology 30, 423 (2012). doi:10.1038/nbt.2197

Authors: Barton F Haynes, Garnett Kelsoe, Stephen C Harrison & Thomas B Kepler

]]> B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study Barton F Haynes Garnett Kelsoe Stephen C Harrison Thomas B Kepler doi:10.1038/nbt.2197 Nature Biotechnology 30, 423 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2197 http://dx.doi.org/10.1038/nbt.2197 30 5 Research 423 433 http://dx.doi.org/10.1038/nbt.2197 Performance comparison of benchtop high-throughput sequencing platforms http://feeds.nature.com/~r/nbt/rss/current/~3/oGguZQ-AmZw/nbt.2198 Small sequencing machines no bigger than a laser printer have many potential applications in diagnostics and public health. Loman et al. compare the quality, throughput and cost of instruments from Illumina, Roche and Life Technologies. Performance comparison of benchtop high-throughput sequencing platforms

Nature Biotechnology 30, 434 (2012). doi:10.1038/nbt.2198

Authors: Nicholas J Loman, Raju V Misra, Timothy J Dallman, Chrystala Constantinidou, Saheer E Gharbia, John Wain & Mark J Pallen

]]> Performance comparison of benchtop high-throughput sequencing platforms Nicholas J Loman Raju V Misra Timothy J Dallman Chrystala Constantinidou Saheer E Gharbia John Wain Mark J Pallen doi:10.1038/nbt.2198 Nature Biotechnology 30, 434 (2012) 2012-04-22 Nature Biotechnology 2012-04-22 10.1038/nbt.2198 http://dx.doi.org/10.1038/nbt.2198 30 5 Research 434 439 http://dx.doi.org/10.1038/nbt.2198 Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting http://feeds.nature.com/~r/nbt/rss/current/~3/_RsbLF3nh_k/nbt.2183 Functional genomics requires facile methods to recover sequences of interest. Fu et al. show that the phage proteins RecE and RecT mediate recombination between linear DNA fragments and can facilitate natural product discovery. Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting

Nature Biotechnology 30, 440 (2012). doi:10.1038/nbt.2183

Authors: Jun Fu, Xiaoying Bian, Shengbaio Hu, Hailong Wang, Fan Huang, Philipp M Seibert, Alberto Plaza, Liqiu Xia, Rolf Müller, A Francis Stewart & Youming Zhang

]]> Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting Jun Fu Xiaoying Bian Shengbaio Hu Hailong Wang Fan Huang Philipp M Seibert Alberto Plaza Liqiu Xia Rolf Müller A Francis Stewart Youming Zhang doi:10.1038/nbt.2183 Nature Biotechnology 30, 440 (2012) 2012-04-29 Nature Biotechnology 2012-04-29 10.1038/nbt.2183 http://dx.doi.org/10.1038/nbt.2183 30 5 Research 440 446 http://dx.doi.org/10.1038/nbt.2183 A proteomics approach for the identification and cloning of monoclonal antibodies from serum http://feeds.nature.com/~r/nbt/rss/current/~3/rTMhExT6f_I/nbt.2167 The ability to identify antibodies circulating in the bloodstream would advance immunology and vaccinology research and the development of therapeutics. Cheung et al. couple proteomics with next-generation sequencing of RNA from B cells to clone antibodies directly from the sera of immunized rabbits and mice. A proteomics approach for the identification and cloning of monoclonal antibodies from serum

Nature Biotechnology 30, 447 (2012). doi:10.1038/nbt.2167

Authors: Wan Cheung Cheung, Sean A Beausoleil, Xiaowu Zhang, Shuji Sato, Sandra M Schieferl, James S Wieler, Jason G Beaudet, Ravi K Ramenani, Lana Popova, Michael J Comb, John Rush & Roberto D Polakiewicz

]]> A proteomics approach for the identification and cloning of monoclonal antibodies from serum Wan Cheung Cheung Sean A Beausoleil Xiaowu Zhang Shuji Sato Sandra M Schieferl James S Wieler Jason G Beaudet Ravi K Ramenani Lana Popova Michael J Comb John Rush Roberto D Polakiewicz doi:10.1038/nbt.2167 Nature Biotechnology 30, 447 (2012) 2012-03-25 Nature Biotechnology 2012-03-25 10.1038/nbt.2167 http://dx.doi.org/10.1038/nbt.2167 30 5 Research 447 452 http://dx.doi.org/10.1038/nbt.2167 Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation http://feeds.nature.com/~r/nbt/rss/current/~3/n75DFkI1jso/nbt.2158 Methods for specific gene silencing have advanced as far as clinical trials, but a similar set of tools does not exist for increasing gene expression. Modarresi et al. demonstrate gene-specific upregulation in vivo by treating mice with oligonucleotides that inhibit the function of natural antisense transcripts. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation

Nature Biotechnology 30, 453 (2012). doi:10.1038/nbt.2158

Authors: Farzaneh Modarresi, Mohammad Ali Faghihi, Miguel A Lopez-Toledano, Roya Pedram Fatemi, Marco Magistri, Shaun P Brothers, Marcel P van der Brug & Claes Wahlestedt

]]> Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation Farzaneh Modarresi Mohammad Ali Faghihi Miguel A Lopez-Toledano Roya Pedram Fatemi Marco Magistri Shaun P Brothers Marcel P van der Brug Claes Wahlestedt doi:10.1038/nbt.2158 Nature Biotechnology 30, 453 (2012) 2012-03-25 Nature Biotechnology 2012-03-25 10.1038/nbt.2158 http://dx.doi.org/10.1038/nbt.2158 30 5 Research 453 459 http://dx.doi.org/10.1038/nbt.2158 FLASH assembly of TALENs for high-throughput genome editing http://feeds.nature.com/~r/nbt/rss/current/~3/F9mg97kkHDs/nbt.2170 Transcription activator–like effector nucleases (TALENs) enable genetic modification at specific sites in a genome. Reyon et al. present a method for high-throughput generation of TALENs, facilitating large-scale genome engineering. FLASH assembly of TALENs for high-throughput genome editing

Nature Biotechnology 30, 460 (2012). doi:10.1038/nbt.2170

Authors: Deepak Reyon, Shengdar Q Tsai, Cyd Khayter, Jennifer A Foden, Jeffry D Sander & J Keith Joung

]]> FLASH assembly of TALENs for high-throughput genome editing Deepak Reyon Shengdar Q Tsai Cyd Khayter Jennifer A Foden Jeffry D Sander J Keith Joung doi:10.1038/nbt.2170 Nature Biotechnology 30, 460 (2012) 2012-04-08 Nature Biotechnology 2012-04-08 10.1038/nbt.2170 http://dx.doi.org/10.1038/nbt.2170 30 5 Research 460 465 http://dx.doi.org/10.1038/nbt.2170 Personal medicine—the new banking crisis http://feeds.nature.com/~r/nbt/rss/current/~3/z2ZQYRnFdPk/nbt0512-466a Personal medicine—the new banking crisis

Nature Biotechnology 30, 466 (2012). doi:10.1038/nbt0512-466a

Authors: Christopher Thomas Scott, Timothy Caulfield, Emily Borgelt & Judy Illes

]]> Personal medicine—the new banking crisis Christopher Thomas Scott Timothy Caulfield Emily Borgelt Judy Illes doi:10.1038/nbt0512-466a Nature Biotechnology 30, 466 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-466a http://dx.doi.org/10.1038/nbt0512-466a 30 5 Erratum 466 466 http://dx.doi.org/10.1038/nbt0512-466a Existing agbiotech traits continue global march http://feeds.nature.com/~r/nbt/rss/current/~3/UynMXmEmtiE/nbt0512-466b Existing agbiotech traits continue global march

Nature Biotechnology 30, 466 (2012). doi:10.1038/nbt0512-466b

Author: Andrew Marshall

]]> Existing agbiotech traits continue global march Andrew Marshall doi:10.1038/nbt0512-466b Nature Biotechnology 30, 466 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-466b http://dx.doi.org/10.1038/nbt0512-466b 30 5 Erratum 466 466 http://dx.doi.org/10.1038/nbt0512-466b Around the world in a month http://feeds.nature.com/~r/nbt/rss/current/~3/baouYFvrzCg/nbt0512-466c Around the world in a month

Nature Biotechnology 30, 466 (2012). doi:10.1038/nbt0512-466c

]]> Around the world in a month doi:10.1038/nbt0512-466c Nature Biotechnology 30, 466 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-466c http://dx.doi.org/10.1038/nbt0512-466c 30 5 Erratum 466 466 http://dx.doi.org/10.1038/nbt0512-466c Fate of novel painkiller mAbs hangs in balance http://feeds.nature.com/~r/nbt/rss/current/~3/Q3jFYjsNh4M/nbt0512-466d Fate of novel painkiller mAbs hangs in balance

Nature Biotechnology 30, 466 (2012). doi:10.1038/nbt0512-466d

Author: Ken Garber

]]> Fate of novel painkiller mAbs hangs in balance Ken Garber doi:10.1038/nbt0512-466d Nature Biotechnology 30, 466 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt0512-466d http://dx.doi.org/10.1038/nbt0512-466d 30 5 Erratum 466 466 http://dx.doi.org/10.1038/nbt0512-466d First-quarter biotech job picture http://feeds.nature.com/~r/nbt/rss/current/~3/SLVHpKfPwhk/nbt.2212 First-quarter biotech job picture

Nature Biotechnology 30, 467 (2012). doi:10.1038/nbt.2212

Author: Michael Francisco

]]> First-quarter biotech job picture Michael Francisco doi:10.1038/nbt.2212 Nature Biotechnology 30, 467 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2212 http://dx.doi.org/10.1038/nbt.2212 30 5 Careers and Recruitment 467 467 http://dx.doi.org/10.1038/nbt.2212 People http://feeds.nature.com/~r/nbt/rss/current/~3/a6xkUwY6hAo/nbt.2219 People

Nature Biotechnology 30, 468 (2012). doi:10.1038/nbt.2219

]]> People doi:10.1038/nbt.2219 Nature Biotechnology 30, 468 (2012) 2012-05-07 Nature Biotechnology 2012-05-07 10.1038/nbt.2219 http://dx.doi.org/10.1038/nbt.2219 30 5 Careers and Recruitment 468 468 http://dx.doi.org/10.1038/nbt.2219